GSK and Alfasigma ink agreement for worldwide rights for linerixibat

(Alliance News) - GSK PLC on Monday announced a global licence deal with Alfasigma Spa for the worldwide rights for linerixibat, an investigational treatment for cholestatic pruritus in primary biliary cholangitis.

Under the deal, Bologna, Italy-based pharmaceutical company, Alfasigma, will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat.

In return, London-based pharmaceutical firm GSK will receive USD300 million upfront from Alfasigma, and a further USD100 million, upon US Food & Drug Administration approval for linerixibat, which is expected before closing based on a March 24 target date.

FTSE 100-listed GSK is also eligible for USD20 million on EU and UK approval, up to USD270 million in sales-based milestones and tiered double-digit royalties on global net sales.

Linerixibat has been granted orphan drug designation in the US, EU and Japan, and is under regulatory review in multiple markets following positive phase III Glisten trial results. The drug is not yet approved anywhere.

Shares in GSK were down 0.9% at 2,020.40 pence each in London on Monday. The wider FTSE 100 was down 1.7%.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Glaxosmithkline